How does lifecycle management keep a marketing authorization current, without variations interrupting supply?

A marketing authorization is not a state, it is an inventory that has to be maintained. The effort does not sit where people expect it: not in the dossier but in the classification. Whether a change counts as type IA, IB or II under Regulation (EC) No 1234/2008 decides whether you may ship immediately, wait thirty days, or wait for approval, and the same question arises again, in a different form, in the US as CBE-0, CBE-30 or a prior approval supplement under 21 CFR 314.70.

The second lever is grouping. Sending the same change through twenty countries individually costs twenty times the fee and the review; Articles 7 and 20 of the regulation expressly provide for grouping and work sharing, and for larger portfolios the difference between the two routes is the single biggest item in the annual lifecycle budget.

The third is the deadline without an owner. Renewal under Article 24 of Directive 2001/83/EC, PSUR data lock points from the EURD list, the annual report under 21 CFR 314.81(b)(2): these clocks run on regardless of any project and go unnoticed until one is missed. For medical devices, EU 2017/745 adds that a technical change can trigger something in regulatory terms that development never sees, up to the question of whether the Article 120 transitional provision still holds.